Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), John D. Hainsworth(Sarah Cannon), Robert R. McWilliams(Mayo Clinic in Arizona), Charles Swanton(The Francis Crick Institute), David R. Spigel(Sarah Cannon), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Katja Schulze, Ari M. Vanderwalde(West Cancer Center), Herbert I. Hurwitz(Duke Medical Center), Razelle Kurzrock(Medical College of Wisconsin), Vaikunth Cuchelkar, Marwan Fakih(City of Hope), Steven Blotner, Howard A. Burris(Deaconess Hospital), Alyssa Stone, Ron Bose(University Hospitals Seidman Cancer Center), Mary Beattie, Christopher J. Sweeney(The University of Adelaide)
Cited by 564
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k